HERSHBERG ROBERT

SEC source: 0001601830-26-000119 · wk-form4_1791410900.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2030-03-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.

SEC source: 0001601830-26-000119 · wk-form4_1791410900.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,156

SEC source: 0001601830-26-000119 · wk-form4_1791410900.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.

SEC source: 0001140361-26-036379 · form4.xml · derivative · entry 5

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 121,968 shares

Expires 2036-06-04

F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001140361-26-036379 · form4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,000 shares

Expires 2035-11-05

F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001140361-26-036379 · form4.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,394 shares

Expires 2032-10-20

F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001140361-26-036379 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 404,869 shares

Expires 2030-07-08

F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001140361-26-036379 · form4.xml · derivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,858 shares

Expires 2030-06-07

F2 · price: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001274139-26-000004 · form4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was fully vested and exercisable and would have expired on October 18, 2026.

SEC source: 0001274139-26-000004 · form4.xml · nonDerivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,683

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001274139-26-000004 · form4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,347

F1 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001274139-26-000004 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,347

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-26-028137 · form4.xml · derivative · entry 5

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 404,869

Underlying: Common Stock · 51,142 shares

Expires 2030-07-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.

F3 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001140361-26-028137 · form4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,858

Underlying: Common Stock · 48,858 shares

Expires 2030-06-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.

F3 · derivative.exercise_date: The stock option is fully vested.

SEC source: 0001140361-26-028137 · form4.xml · nonDerivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,000

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.

F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.90 to $5.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-26-028137 · form4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.

SEC source: 0001140361-26-028137 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,858

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.

SEC source: 0001601830-26-000087 · wk-form4_1782160351.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,156

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001140361-26-024524 · form4.xml · derivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,968

Underlying: Common Stock · 121,968 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date.

SEC source: 0001274139-26-000001 · primary_doc.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,347

SEC source: 0001274139-25-000003 · primary_doc.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,722

SEC source: 0001140361-25-040856 · form4.xml · derivative · entry 4

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,000

Underlying: Common Shares · 103,000 shares

Expires 2035-11-05

F3 · derivative.exercise_date: The stock option shall vest in full on the first anniversary of the grant date.

SEC source: 0001140361-25-040856 · form4.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,394

Underlying: Common Shares · 62,394 shares

Expires 2032-10-20

F1 · shares: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.

F2 · derivative.exercise_date: The stock option is fully vested as of the grant date.

SEC source: 0001140361-25-040856 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,716

Underlying: Common Shares · 97,716 shares

Expires 2030-06-07

F1 · shares: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.

F2 · derivative.exercise_date: The stock option is fully vested as of the grant date.

SEC source: 0001140361-25-040856 · form4.xml · derivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,011

Underlying: Common Shares · 456,011 shares

Expires 2030-07-05

F1 · shares: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.

F2 · derivative.exercise_date: The stock option is fully vested as of the grant date.

SEC source: 0001193125-25-206257 · ownership.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

SEC source: 0001601830-25-000110 · wk-form4_1750713796.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,031

Underlying: Class A Common Stock · 44,031 shares

Expires 2035-06-18

F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001601830-25-000110 · wk-form4_1750713796.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,732

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001062993-25-005300 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,690

SEC source: 0001062993-25-004803 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,726

Underlying: Common Stock · 23,726 shares

Expires 2035-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-25-004803 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,690

SEC source: 0000950170-25-018822 · ownership.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,101,498

F1 · shares: 1. Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: 2. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices between $1.7551 and $1.7745. The Reporting Person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-018822 · ownership.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,113,399

F1 · shares: 1. Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001601830-24-000072 · wk-form4_1717625527.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,193

Underlying: Class A Common Stock · 26,193 shares

Expires 2034-06-03

F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001601830-24-000072 · wk-form4_1717625527.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,716

F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.

SEC source: 0001062993-24-005772 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,044

Underlying: Common Stock · 48,044 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-24-005772 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,296

SEC source: 0000950170-24-014063 · ownership.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,885

Underlying: Common Stock · 226,885 shares

Expires 2034-02-07

F4 · derivative.exercise_date: The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 8, 2025 and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0000950170-24-014063 · ownership.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,128,033

F3 · shares: Represents RSUs which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 8, 2024, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.

SEC source: 0000950170-24-014063 · ownership.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 953,831

F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.

SEC source: 0001209191-23-038840 · doc4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,224

Underlying: Class A Common Stock · 25,224 shares

Expires 2033-06-16

F2 · shares: The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001209191-23-038840 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,619

F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer.

SEC source: 0001209191-23-035051 · doc4.xml · derivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-06-06

F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

SEC source: 0001062993-23-006334 · form4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,329

Underlying: Common Stock · 23,329 shares

Expires 2033-03-06

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

SEC source: 0001062993-23-006334 · form4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,968

SEC source: 0001209191-23-006994 · doc4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,000 shares

Expires 2023-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-23-006994 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-003852 · doc4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,950

Underlying: Common Stock · 381,950 shares

Expires 2033-01-31

F2 · derivative.exercise_date: The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 1, 2024 and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.

SEC source: 0000899243-23-003852 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 965,428

F1 · shares: Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 1, 2023, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.

SEC source: 0001209191-22-037637 · doc4.xml · derivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,290

Underlying: Class A Common Stock · 36,290 shares

Expires 2032-06-14